Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Why Will Bioasis Fail?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Jul 25, 2022 5:44pm
150 Views
Post# 34849494

RE:Why Will Bioasis Fail?

RE:Why Will Bioasis Fail?I don't know if Bioasis will fail but I know what I'm concerned about as a shareholder.

I think BTI is at 13.5 cents because of investor concerns about the upcoming Phase II GBS trial financing and dilution and the NASDAQ listing.  I suspect we'll be going into both at current stock prices.  It would take a partner's clinical trial starting very soon to change that IMO.

The NASDAQ listing is supposed to be a good thing for current investors but I'm less than convinced that will be true. The extent of the dilution is a major concern for me.  A short clip from a recent Tim Ferriss interview (starting at 1:31:35) is also a good reminder.

[url=https://www.youtube.com/watch?v=JwiswTQkvew&]Link works?[/url]
https://www.youtube.com/watch?v=JwiswTQkvew&

My preference would be for management to sell the company.  I said a year or two ago I would vote "yes" for a buyout at $2.00 US a share.  I'd certainly take that today.  Push comes to shove I'd go down to $1.00 US and still vote "yes". 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities